Cargando…
Silexan for treatment of psychiatric manifestations in the context of COVID-19: a case series
INTRODUCTION: Silexan manufactured from Lavandula angustifolia showed favorable safety and efficacy in subthreshold and generalized anxiety disorder (GAD), mixed anxiety and depressive disorder (MADD), and further, especially subsyndromal psychiatric manifestations including depression, sleep distur...
Autores principales: | Bartova, L., Dold, M., Fugger, G., Weidenauer, A., Rujescu-Balcu, D., Kasper, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479386/ http://dx.doi.org/10.1192/j.eurpsy.2023.1690 |
Ejemplares similares
-
Silexan for treatment of anxiety and depression in the context of COVID-19
por: Bartova, Lucie, et al.
Publicado: (2023) -
Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials
por: Dold, Markus, et al.
Publicado: (2023) -
Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited
por: Bartova, Lucie, et al.
Publicado: (2022) -
Psychotherapy employed additionally to Psychopharmacotherapy is not related to Better Treatment Outcome in Major Depressive Disorder
por: Bartova, L., et al.
Publicado: (2022) -
PS75. Psychopharmacoepidemiology of Major Depressive Disorder in European Tertiary Psychiatric Treatment Centers
por: Bartova, Lucie, et al.
Publicado: (2016)